CN Patent

CN114129566A — 用于治疗肺腺癌的met、vegfr和ret的抑制剂

Assigned to Exelixis Inc · Expires 2022-03-04 · 4y expired

What this patent protects

本发明涉及用MET、VEGF和RET的抑制剂对患者、具体地肺腺癌患者、更具体地患有KIF5B‑RET融合阳性非小细胞肺癌患者中的癌症的治疗，所述抑制剂是式(I)的化合物或其药学上可接受的盐。

USPTO Abstract

本发明涉及用MET、VEGF和RET的抑制剂对患者、具体地肺腺癌患者、更具体地患有KIF5B‑RET融合阳性非小细胞肺癌患者中的癌症的治疗，所述抑制剂是式(I)的化合物或其药学上可接受的盐。

Drugs covered by this patent

larotrectinib-sulfate (LAROTRECTINIB SULFATE)

Patent Metadata

Patent number: CN114129566A
Jurisdiction: CN
Classification: —
Expires: 2022-03-04
Drug substance claim: No
Drug product claim: No
Assignee: Exelixis Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.